Next Article in Journal
Macrophages—Target and Tool in Tumor Treatment: Insights from Ovarian Cancer
Previous Article in Journal
Cervical Cancer Screening in the HPV-Vaccinated and Digital Era: Reassessing Strategies in Light of Artificial Intelligence and Evolving Risk
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 17
Issue 19
10.3390/cancers17193181
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Cancers 2022, 14(2), 326.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Lan et al. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Cancers 2022, 14, 326

by
Bin Lan
1,†,
Siyuan Zeng
1,†,
Shuman Zhang
1,
Xiaofan Ren
1,
Yuming Xing
1,
Isabella Kutschick
1,
Susanne Pfeffer
1,
Benjamin Frey
2,
Nathalie Britzen-Laurent
1,
Robert Grützmann
1,
Nils Cordes
3,4,5,6 and
Christian Pilarsky
1,*
1
Department of Surgery, Universitätsklinikum Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany
2
Translational Radiobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany
3
OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany
4
Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology-OncoRay, 01328 Dresden, Germany
5
German Cancer Consortium, Partner Site Dresden: German Cancer Research Center, 69120 Heidelberg, Germany
6
Department of Radiotherapy and Radiation Oncology, University Hospital Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Cancers 2025, 17(19), 3181; https://doi.org/10.3390/cancers17193181
Submission received: 25 September 2025 / Accepted: 29 September 2025 / Published: 30 September 2025
Browse Figure
Versions Notes
Error in Figure
In the original publication [1], there was a mistake in Figure 2C right as published. An error occurred during figure assembly duplicating part of the figure. The corrected Figure 2C right appears below.
The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Lan, B.; Zeng, S.; Zhang, S.; Ren, X.; Xing, Y.; Kutschick, I.; Pfeffer, S.; Frey, B.; Britzen-Laurent, N.; Grützmann, R.; et al. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Cancers 2022, 14, 326. [Google Scholar] [CrossRef] [PubMed]
Cancers 17 03181 g002
Figure 2. DYRK1A knockout enhances radiotherapy efficacy in pancreatic cancer. (A) Western blot of TB32047 and MIA PaCa-2 cells transfected with DYRK1A sgRANs or non-targeting control. (B) A clonogenic assay of TB32047 (left) and MIA PaCa-2 (right) cells with DYRK1A KO and control sgRNA cells was performed after irradiation with different doses of X-rays. The colony numbers were counted and normalized. Data are presented as means of three independent experiments (n = 3). *, p < 0.05; **, p < 0.01; *** and p < 0.001 by 2-tailed unpaired Student’s t test. (C) TB32047 (left) and MIA PaCa-2 (right) single clones and control cells were treated with different doses of radiation followed by clonogenic assays. Representative images of three independent experiments (n = 3) are shown. (D,E) Flow cytometry-based apoptosis analysis of TB32047 (D) and MIA PaCa-2 (E) control and DYRK1A KO single clones irradiated with 5 Gy X-rays after 24 h. Representative images of three independent experiments (n = 3) and statistical analysis are shown. **, p < 0.01; ***, p < 0.001 and ****, p < 0.0001 by 2-tailed unpaired Student’s t test. ns. not significant.
Figure 2. DYRK1A knockout enhances radiotherapy efficacy in pancreatic cancer. (A) Western blot of TB32047 and MIA PaCa-2 cells transfected with DYRK1A sgRANs or non-targeting control. (B) A clonogenic assay of TB32047 (left) and MIA PaCa-2 (right) cells with DYRK1A KO and control sgRNA cells was performed after irradiation with different doses of X-rays. The colony numbers were counted and normalized. Data are presented as means of three independent experiments (n = 3). *, p < 0.05; **, p < 0.01; *** and p < 0.001 by 2-tailed unpaired Student’s t test. (C) TB32047 (left) and MIA PaCa-2 (right) single clones and control cells were treated with different doses of radiation followed by clonogenic assays. Representative images of three independent experiments (n = 3) are shown. (D,E) Flow cytometry-based apoptosis analysis of TB32047 (D) and MIA PaCa-2 (E) control and DYRK1A KO single clones irradiated with 5 Gy X-rays after 24 h. Representative images of three independent experiments (n = 3) and statistical analysis are shown. **, p < 0.01; ***, p < 0.001 and ****, p < 0.0001 by 2-tailed unpaired Student’s t test. ns. not significant.
Cancers 17 03181 g002
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lan, B.; Zeng, S.; Zhang, S.; Ren, X.; Xing, Y.; Kutschick, I.; Pfeffer, S.; Frey, B.; Britzen-Laurent, N.; Grützmann, R.; et al. Correction: Lan et al. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Cancers 2022, 14, 326. Cancers 2025, 17, 3181. https://doi.org/10.3390/cancers17193181

AMA Style

Lan B, Zeng S, Zhang S, Ren X, Xing Y, Kutschick I, Pfeffer S, Frey B, Britzen-Laurent N, Grützmann R, et al. Correction: Lan et al. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Cancers 2022, 14, 326. Cancers. 2025; 17(19):3181. https://doi.org/10.3390/cancers17193181

Chicago/Turabian Style

Lan, Bin, Siyuan Zeng, Shuman Zhang, Xiaofan Ren, Yuming Xing, Isabella Kutschick, Susanne Pfeffer, Benjamin Frey, Nathalie Britzen-Laurent, Robert Grützmann, and et al. 2025. "Correction: Lan et al. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Cancers 2022, 14, 326" Cancers 17, no. 19: 3181. https://doi.org/10.3390/cancers17193181

APA Style

Lan, B., Zeng, S., Zhang, S., Ren, X., Xing, Y., Kutschick, I., Pfeffer, S., Frey, B., Britzen-Laurent, N., Grützmann, R., Cordes, N., & Pilarsky, C. (2025). Correction: Lan et al. CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer. Cancers 2022, 14, 326. Cancers, 17(19), 3181. https://doi.org/10.3390/cancers17193181

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop